Jazz Pharmaceuticals (JAZZ)
NASDAQ: JAZZ
· Real-Time Price · USD
115.40
-2.79 (-2.36%)
At close: May 05, 2025, 3:59 PM
-2.36% (1D)
| Bid | 115.1 |
| Market Cap | 7.11B |
| Revenue (ttm) | 4.07B |
| Net Income (ttm) | 560.12M |
| EPS (ttm) | 8.65 |
| PE Ratio (ttm) | 13.34 |
| Forward PE | 5.2 |
| Analyst | Buy |
| Ask | 115.78 |
| Volume | 120,043 |
| Avg. Volume (20D) | 1,235,328 |
| Open | 117.50 |
| Previous Close | 118.19 |
| Day's Range | 115.33 - 117.81 |
| 52-Week Range | 95.49 - 148.06 |
| Beta | 0.38 |
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2007
Employees 2,800
Stock Exchange NASDAQ
Ticker Symbol JAZZ
Website https://www.jazzpharma.com
Analyst Forecast
According to 13 analyst ratings, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $179, which is an increase of 55.11% from the latest price.
Stock ForecastsNext Earnings Release
Jazz Pharmaceuticals is scheduled to release its earnings on May 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+3.22%
Jazz Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago
+1.02%
Jazz Pharmaceuticals shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $130 to $170.
